Patient characteristics at baseline (mean (SD) unless stated)
| Treatment group | Moxifloxacin | Doxycycline | Azithromycin | Placebo |
|---|---|---|---|---|
| Total (n) | 25 | 25 | 25 | 24 |
| Gender (n, % male) | 17 (68) | 18 (72) | 16 (64) | 18 (75) |
| Age (years) | 70.9 (8.2) | 70.4 (7.0) | 67.9 (8.6) | 68.7 (9.8) |
| BMI (kg/m2) | 26.3 (5.2) | 28.4 (6.4) | 26.6 (6.9) | 26.9 (4.9) |
| Current smoker, n (%) | 16 (64) | 10 (40) | 7 (28) | 8 (33) |
| Pack-years | 53 (27) | 52 (50) | 51 (25) | 56 (50) |
| Number of exacerbations in previous year* | 2.5 (2.1) | 2.1 (1.7) | 2.8 (4.0) | 1.5 (1.4) |
| Inhaled corticosteroid use, n (%) | 21 (84) | 19 (76) | 18 (72) | 13 (57) |
| Bacterial load, log10 cfu/mL† | 8.3 (0.8) | 8.1 (0.7) | 8.1 (0.8) | 7.8 (0.7) |
| Bacterial load, log10 16S copies/g sputum | 9.4 (0.8) | 9.3 (0.73) | 9.0 (0.6) | 9.1 (0.8) |
| FEV1 (L) | 1.4 (0.5) | 1.5 (0.5) | 1.2 (0.5) | 1.5 (0.6) |
| FEV1:FVC | 0.51 (0.10) | 0.51 (0.13) | 0.45 (0.12) | 0.51 (0.12) |
| FEV1, % predicted | 52 (13) | 53 (14) | 44 (17) | 53 (13) |
| FVC (L) | 2.8 (1.1) | 3.0 (1.1) | 2.7 (0.7) | 3.0 (1.0) |
| SGRQ: total score | 51 (14) | 47 (16) | 48 (18) | 46 (19) |
| SGRQ: symptom score | 64 (16) | 62 (24) | 59 (18) | 55 (19) |
| SGRQ: activity score | 67 (21) | 62 (19) | 66 (25) | 61 (24) |
| SGRQ: impact score | 37 (12) | 35 (16) | 35 (18) | 34 (20) |
| Il-1β, log10 pg/mL | 2.3 (0.6) | 1.9 (0.7) | 2.2 (0.8) | 2.1 (0.7) |
| IL-6, log10 pg/mL | 1.9 (0.7) | 1.5 (0.8) | 1.8 (0.8) | 1.6 (0.6) |
| IL-8, log10 pg/mL | 4.3 (0.7) | 3.9 (0.9) | 4.1 (0.7) | 3.8 (0.8) |
*Self-reported exacerbation frequency.
†For those patients with culture results above the threshold of detection.
BMI, body mass index; IL, interleukin; SGRQ, St George's Respiratory Questionnaire.